Refers to a compound of formula (i) wherein: R1 is - CH2 - cycloalkyl C3 C6, alcuilo c1-c4 opcinalmente replaced R11 R2 is H, c1-c4 alkyl R3 is a Heterocyclic Ring containing a saturated C4 C7 Atom and N Atom or optionally and being optionally replaced r1 is H, F Luor, R22 is H, halogen, c1-c4 alkyl, c1-c4 alkoxyl, hydroxyl,Among others, or form a Group - or with R23 - CH2 - or - R23 is H, halogen, c1-c4 alkyl, c1-c4 alkoxyl, hydroxyl, fluoroalcoxilo c1-c4 R24 is H - (CH2) and is n R11 is c1-c4 alkoxyl, hydroxyl n is 0 - 1.Preferred compounds are: N - (1 - acetilpiperidin - 4-yl) - 4 - [5 - (Cyclopropylmethoxy) - 1,3 - benzodioxol - 4-yl] - 6 - methyl - 5h pyrrolo [3,2-d] pyrimidine - 7 - carboxamide 4 - [5 - (Cyclopropylmethoxy) - 1,3 - benzodioxol - 4-yl] - 6 - Methyl - N - (1 - propionilpiperidin - 4-yl) - 5h pyrrolo [3,2-d] pyrimidine - 7 - carboxamide among others. In addition to such a Pharmaceutical composition.This Compound is an inhibitor of phosphodiesterase type 5 is useful in the Treatment or prevention of acute or chronic disease of the AirwaysSE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1 ES -CH2-CICLOALQUILO C3-C6, ALCUILO C1-C4 OPCINALMENTE SUSTITUIDO POR R11 R2 ES H, ALQUILO C1-C4 R3 ES UN ANILLO HETEROCICLICO SATURADO C4-C7 QUE CONTIENE UN ATOMO DE N Y OPCIONALMENTE UN ATOMO DE O Y ESTANDO OPCIONALMENTE SUSTITUIDO R21 ES H, FLUOR R22 ES H, HALOGENO, ALQUILO C1-C4, ALCOXILO C1-C4, HIDROXILO, ENTRE OTROS O FORMA JUNTO A R23 UN GRUPO -O-CH2-O- R23 ES H, HALOGENO, ALQUILO C1-C4, ALCOXILO C1-C4, HIDROXILO, FLUOROALCOXILO C1-C4 R24 ES H Y ES -(CH2)n R11 ES ALCOXILO C1-C4, HIDROXILO n ES 0-1. SON COMPUESTOS PREFERIDOS: N-(1-ACETILPIPERIDIN-4-IL)-4-[5-(CICLOPROPILMETOXI)-1,3-BENZODIOXOL-4-IL]-6-METIL-5H-PIRROLO[3,2-d]PIRIMIDINA-7-CARBOXAMIDA 4-[5-(CICLOPROPILMETOXI)-1,3-BENZODIOXOL-4-IL]-6-METIL-N-(1-PROPIONILPIPERIDIN-4-IL)-5H-PIRROLO[3,2-d]PIRIMIDINA-7-CARBOXAMIDA ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHI
